利巴韦林
传染性
病毒学
2019年冠状病毒病(COVID-19)
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
病毒
抗病毒药物
药品
生物
突变
医学
药理学
突变
疾病
基因
遗传学
传染病(医学专业)
内科学
丙型肝炎病毒
作者
Carlos García‐Crespo,Ana Isabel de Ávila,Isabel Gallego,María Eugenia Soria,Antoni Durán‐Pastor,Pilar Somovilla,Brenda Martínez‐González,Javier Muñoz‐Flores,Pablo Mínguez,Llanos Salar‐Vidal,Mario Esteban‐Muñoz,Elizabeth Cañar‐Camacho,Cristina Ferrer‐Orta,Sonia Zúñiga,Isabel Sola,Luis Enjuanes,Jaime Esteban,R. Fernández‐Roblas,Ignacio Gadea,Jordi Gómez,Núria Verdaguer,Esteban Domingo,Celia Perales
摘要
There is a need for effective anti-COVID-19 treatments, mainly for individuals at risk of severe disease such as the elderly and the immunosuppressed. Drug repositioning has proved effective in identifying drugs that can find a new application for the control of coronavirus disease, in particular COVID-19. The purpose of the present study was to find synergistic antiviral combinations for COVID-19 based on lethal mutagenesis.
科研通智能强力驱动
Strongly Powered by AbleSci AI